Please assess the completion status of the following clinical trial:

Trial Title: Aripiprazole Once-monthly in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Patients will be recruited among those who complete treatment with aripiprazole in Study 14724A / NCT01795547.~Inclusion Criteria:~* The patient is judged to potentially benefit from 24-week treatment with aripiprazole once-monthly according to the clinical opinion of the investigator.~* The patient agrees to protocol-defined use of effective contraception.~Exclusion Criteria:~* The patient has been diagnosed with a primary psychiatric disorder other than schizophrenia during Study 14724A / NCT01795547.~* The patient has a clinically significant unstable illness diagnosed during Study 14724A / NCT01795547.~* The patient is at significant risk of harming himself/herself or others according to the investigator's judgement or according to Columbia-Suicide Severity Rating Scale (C-SSRS).~* The patient has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability or efficacy, or interfere with the conduct or interpretation of the study.~* The patient has one or more clinical laboratory test values outside the reference range, based on the blood or urine samples taken during the conduct of Study 14724A / NCT01795547 that are, in the investigator's opinion, of potential risk to the patient's safety.~* The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole once-monthly (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).